Laboratory of Nanomedicine, Dept. of Cell Research and Immunology, George S. Wise Faculty of Life Science, Tel Aviv University, Tel Aviv 69978, Israel Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv, 69978, Israel.
J Control Release. 2012 Jul 20;161(2):600-8. doi: 10.1016/j.jconrel.2011.12.034. Epub 2011 Dec 30.
Lipid-based nanoparticles (LNPs) hold great promise as delivery vectors in the treatment of cancer, inflammation, and infections and are already used in clinical practice. Numerous strategies based on LNPs are being developed to carry drugs into specific target sites. The common denominator for all of these LNPs-based platforms is to improve the payloads' pharmacokinetics, biodistribution, stability and therapeutic benefit, and to reduce to minimal adverse effects. In addition, the delivery system must be biocompatible and non-toxic and avoid undesirable interactions with the immune system. In order to achieve optimal benefits from these delivery strategies, interactions with the immune system must be thoroughly investigated. This report will center on the interactions of LNPs with different subsets of leukocytes and will detail representative examples of suppression or activation of the immune system by these carriers. By understanding the interactions of LNPs with the innate and the adaptive arms of the immune system it might be possible to attain improved therapeutic benefits and to avoid immune toxicity.
基于脂质的纳米颗粒（LNPs）作为癌症、炎症和感染治疗的载体具有巨大的应用前景，目前已经在临床实践中得到应用。为了将药物递送到特定的靶位，人们正在开发基于 LNPs 的多种策略。所有这些基于 LNPs 的平台的共同点是改善有效载荷的药代动力学、生物分布、稳定性和治疗效果，并将不良反应最小化。此外，递药系统必须具有生物相容性和低毒性，并避免与免疫系统产生不良相互作用。为了从这些递药策略中获得最佳疗效，必须彻底研究与免疫系统的相互作用。本报告将重点介绍 LNPs 与白细胞不同亚群的相互作用，并详细介绍这些载体对免疫系统的抑制或激活的代表性实例。通过了解 LNPs 与固有免疫和适应性免疫系统的相互作用，有可能实现治疗效果的改善，并避免免疫毒性。
